Evidence map›Paper›PMID 39458581›Full record

ArticlePharmaceutics2024

Buprenorphine Transdermal Delivery System: Bioequivalence Assessment and Adhesion Performance of Two Patch Formulations.

Marcelo Gomes Davanço, Miguel Fortuny, Alejandro Scasso, Jessica Meulman, Fernando Costa, Thalita Martins da Silva, Débora Renz Barreto Vianna, Leonardo de Souza Teixeira, Karini Bruno Bellorio, Ana Carolina Costa Sampaio and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Marcelo Gomes DavançoClinical Research Unit, Adium S.A., São Paulo 04794-000, Brazil.ORCID 0000-0002-1684-6591
Miguel FortunyR&D Department, Amarin Technologies S.A., Buenos Aires C1416BQG, Argentina.
Alejandro ScassoR&D Department, Amarin Technologies S.A., Buenos Aires C1416BQG, Argentina.
Jessica MeulmanClinical Research Unit, Adium S.A., São Paulo 04794-000, Brazil.
Fernando CostaCorporate Department of Clinical Studies, Adium S.A. Headquarters, Buenos Aires B1603APO, Argentina.
Thalita Martins da SilvaClinical Research Unit, Adium S.A., São Paulo 04794-000, Brazil.ORCID 0000-0001-7685-3120
Débora Renz Barreto ViannaClinical Research Unit, Adium S.A., São Paulo 04794-000, Brazil.ORCID 0000-0002-1338-9911
Leonardo de Souza TeixeiraBioequivalence Unit, Instituto de Ciências Farmacêuticas de Estudos e Pesquisas Ltda., Goiânia 74935-530, Brazil.
Karini Bruno BellorioBioequivalence Unit, Instituto de Ciências Farmacêuticas de Estudos e Pesquisas Ltda., Goiânia 74935-530, Brazil.
Ana Carolina Costa SampaioBioequivalence Unit, Instituto de Ciências Farmacêuticas de Estudos e Pesquisas Ltda., Goiânia 74935-530, Brazil.
Celso Francisco Pimentel VespasianoClinical Research Unit, Adium S.A., São Paulo 04794-000, Brazil.ORCID 0000-0001-7557-199X

Funding

Adium S.A. PBIO020/19
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

adhesionbioequivalencebuprenorphineopioidpatchpharmacokineticstransdermal delivery system

Identifiers

PMID39458581
PMCPMC11510105

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.